Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06VGD
|
||||
| Former ID |
DNC007859
|
||||
| Drug Name |
ACENAPHTHOQUINONE
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H6O2
|
||||
| Canonical SMILES |
C1=CC2=C3C(=C1)C(=O)C(=O)C3=CC=C2
|
||||
| InChI |
1S/C12H6O2/c13-11-8-5-1-3-7-4-2-6-9(10(7)8)12(11)14/h1-6H
|
||||
| InChIKey |
AFPRJLBZLPBTPZ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cholinesterase | Target Info | Inhibitor | [1] | |
| Liver carboxylesterase | Target Info | Inhibitor | [1] | ||
| KEGG Pathway | Drug metabolism - other enzymes | ||||
| Metabolic pathways | |||||
| PANTHER Pathway | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | ||||
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | |||||
| Nicotinic acetylcholine receptor signaling pathway | |||||
| Pathway Interaction Database | E2F transcription factor network | ||||
| WikiPathways | Irinotecan PathwayWP2884:NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Heroin metabolism | |||||
| Irinotecan Pathway | |||||
| Fluoropyrimidine Activity | |||||
| Phase I biotransformations, non P450 | |||||
| References | |||||
| REF 1 | J Med Chem. 2007 Nov 15;50(23):5727-34. Epub 2007 Oct 17.Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.